| Disease Domain | Count |
|---|---|
| Neoplasms | 1 |
| Immune System Diseases | 1 |
| Hemic and Lymphatic Diseases | 1 |
| Top 5 Drug Type | Count |
|---|---|
| Small molecule drug | 1 |
| Radionuclide Drug Conjugates (RDC) | 1 |
| Therapeutic radiopharmaceuticals | 1 |
| Live biotherapeutic products | 1 |
| Top 5 Target | Count |
|---|---|
| Na/K-ATPase(Sodium/potassium-transporting ATPase) | 1 |
Target- |
Mechanism Bacteria replacements [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism TOP1 inhibitors |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism Na/K-ATPase modulators |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhasePhase 2 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Jul 2012 |
Sponsor / Collaborator |
Start Date07 Apr 2008 |
Sponsor / Collaborator |

| Drug(Targets) | Indications | Global Highest Phase |
|---|---|---|
Rostafuroxine ( Na/K-ATPase ) | Hypertension More | Phase 2 |
STP-206 | Enterocolitis More | Phase 2 |
AvidinOx-Lu-177-DOTA-Biotin | Colorectal Cancer More | Phase 1 |
MED-27 ( TBXA2R x TXA2 synthase ) | Thrombosis More | Discontinued |
ST-570 ( DRDs ) | Hypertension More | Discontinued |





